Brazil Neurology Clinical Trials Market Report 2022 to 2030

Brazil Neurology Clinical Trials Market Analysis

$ 3999

The Brazil Neurology Clinical Trials market is projected to grow from $130.8 Mn in 2022 to $216.4 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological disorders and government initiatives to support clinical research in the country. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Biogen Inc & Aché Laboratórios Farmacêuticos S.A.

ID: IN10BRCT005 CATEGORY: Clinical Trials GEOGRAPHY: Brazil AUTHOR: Vidhi

Buy Now

Brazil Neurology Clinical Trials Market Executive Summary

The Brazil Neurology Clinical Trials market is projected to grow from $130.8 Mn in 2022 to $216.4 Mn by 2030, registering a CAGR of 6.5% during the forecast period of 2022 - 2030. According to the Global Population Ageing 2019 study, the population of people aged 65 and more in Brazil in 2019 was 19.526 million (9.3%), and this figure is expected to rise to 30.413 million (13.6%) by 2030. The geriatric population is predicted to increase in the next years, and the ageing population is more susceptible to neurological illnesses such as Parkinson's disease and Alzheimer's disease, which will drive the market in the future.

The neurology clinical trials environment in Brazil is currently expanding, with a rising number of studies being undertaken in the nation. Brazil has a big and diversified population with a high frequency of neurological illnesses, which makes it a desirable destination for neurology clinical trials. Novartis, Biogen, Roche, Eli Lilly, and Pfizer are among the leading pharmaceutical firms performing neurology clinical studies in Brazil. These firms are working on novel therapeutics for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. Apart from major pharmaceutical giants, there are a number of Brazilian biotech firms engaged in the neurology field. These firms are working to provide novel treatments for a variety of neurological conditions, including neurodegenerative diseases and stroke.

The Brazilian government has taken initiatives to assist clinical research in the nation, such as the establishment of the National Health Research Ethics Committee, which is in charge of ensuring that clinical trials adhere to ethical and scientific standards. Moreover, the nation boasts a sizable and highly-trained medical profession, as well as a number of world-class research facilities and hospitals.

Brazil Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

One of the primary factors is Brazil's huge and diversified population, which makes it an ideal locale for clinical trials. This is especially true for neurology clinical trials since neurological illnesses such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are common in Brazil.

Another driver is the country's highly educated medical staff and world-class research institutes, which give a solid framework for performing clinical trials. Moreover, the Brazilian government has taken initiatives to assist clinical research in the nation, such as the establishment of the National Health Research Ethics Committee, which verifies that clinical trials adhere to ethical and scientific standards.

Market Restraints

There are also numerous constraints affecting the Brazilian neurology clinical trials market. The complicated regulatory framework, which can be time-consuming and expensive for firms wishing to perform clinical trials in the nation, is one of the significant challenges. Moreover, regulatory obstacles might obstruct the process of acquiring required permissions for clinical studies.

Another challenge is the country's economic and political uncertainty, which may have an influence on the healthcare sector and the clinical trials business. In recent years, Brazil has had a variety of economic and political issues, including high inflation and political instability, which may generate uncertainty for corporations intending to invest in the nation.

Competitive Landscape

Key Players

Novartis AG
Biogen Inc.
Roche Holding AG
Pfizer Inc.
Eli Lilly and Company
Sanofi S.A.
Aché Laboratórios Farmacêuticos S.A. (BRA)
Biolab Sanus Farmacêutica Ltda (BRA)
EMS Sigma Pharma (BRA)
Eurofarma Laboratórios S.A. (BRA)
Cristália Produtos Químicos Farmacêuticos Ltda. (BRA)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.